拉米夫定治疗临床表现为肾炎综合征的乙型肝炎病毒相关性肾炎的疗效观察

Therapy reaction of lamivudine in hepatitis B virus-associated glomerulonephritis patients.

目的观察拉米夫定治疗临床表现为肾炎综合征的乙型肝炎病毒相关性肾炎(HBV-GN)的疗效。方法32例符合条件的HBV-GN患者,随机分成治疗组和对照组,治疗组口服拉米夫定100mg/d,对照组服用血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体拮抗剂(ARB),治疗12个月,随访6个月。结果拉米夫定治疗组蛋白尿较对照组明显减少,肾功能稳定,仅1例患者因使用拉米夫定出现YVDD变异,无明显不良反应发生。结论拉米夫定治疗临床表现为肾炎综合征的乙型肝炎病毒相关性肾炎安全有效。

Objective To explore therapy reaction of lamivudine in hepatitis B virus - associated glomerulonephfitis patients. Methods 32 HBV - GN patients were divided into therapy group and control group, therapy group was treated with lamivudine 100 mg/d, while control group was treated with ACEI or ARB, all patients were treated for 12months, follow up 6 months. Results The degree of proteinufia reduction was significantly lower in lamivudine treated group, most of the cases were responsive to therapy, renal function were stable, only one patient showed YVDD mutations, no severe side effects were reported. Conclusion Our studies have provided the evidence that HBV - GN has beneficial response to lamivudine therapy with no severe side effects.